	US 12,433,938 B2
	Alkaline phosphatase polypeptides and methods of use thereof
Walter C. Voegtli, Killingworth, CT (US); Michael Baranello, Boston, MA (US); and Keith Bouchard, Boston, MA (US)
Assigned to Alexion Pharmaceuticals, Inc., Boston, MA (US)
Filed by Alexion Pharmaceuticals, Inc., Boston, MA (US)
Filed on Dec. 9, 2020, as Appl. No. 17/117,099.
Claims priority of provisional application 62/945,431, filed on Dec. 9, 2019.
Prior Publication US 2021/0169994 A1, Jun. 10, 2021
Int. Cl. A61K 38/46 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61P 19/08 (2006.01); C12N 9/16 (2006.01)

CPC A61K 38/465 (2013.01) [A61K 9/0019 (2013.01); A61K 47/02 (2013.01); A61P 19/08 (2018.01); C12N 9/16 (2013.01); C12Y 301/03001 (2013.01); C07K 2319/30 (2013.01)]

17 Claims

1. A polypeptide comprising: (1) a recombinant alkaline phosphatase having at least one mutation selected from the group consisting of E108S, E108T, E108Q, E108M, E108K, E108L, M384R, and L385T relative to SEQ ID NO: 1 and (2) a bone targeting moiety comprising from 3 to 30 consecutive aspartate or glutamate residues, wherein the polypeptide comprises an amino acid sequence with at least 90% sequence identity to any one of SEQ ID NOs: 72, 123, 155, or 177, wherein the original residue before mutation is shown in SEQ ID NO: 1, and the position numbers are relative to SEQ ID NOs: 1, 72, 123, 155, and 177.